The TROG 15.01 stereotactic prostate adaptive radiotherapy utilizing kilovoltage intrafraction monitoring (SPARK) clinical trial database

IF 3.2 2区医学 Q1 RADIOLOGY, NUCLEAR MEDICINE & MEDICAL IMAGING

Medical physics Pub Date : 2024-11-23 DOI:10.1002/mp.17529

Chandrima Sengupta, Doan Trang Nguyen, Yifan Li, Emily Hewson, Helen Ball, Ricky O'Brien, Jeremy Booth, John Kipritidis, Thomas Eade, Andrew Kneebone, George Hruby, Regina Bromley, Peter Greer, Jarad Martin, Perry Hunter, Lee Wilton, Trevor Moodie, Amy Hayden, Sandra Turner, Nicholas Hardcastle, Shankar Siva, Keen-Hun Tai, Sankar Arumugam, Mark Sidhom, Per Poulsen, Val Gebski, Alisha Moore, Paul Keall

{"title":"The TROG 15.01 stereotactic prostate adaptive radiotherapy utilizing kilovoltage intrafraction monitoring (SPARK) clinical trial database","authors":"Chandrima Sengupta, Doan Trang Nguyen, Yifan Li, Emily Hewson, Helen Ball, Ricky O'Brien, Jeremy Booth, John Kipritidis, Thomas Eade, Andrew Kneebone, George Hruby, Regina Bromley, Peter Greer, Jarad Martin, Perry Hunter, Lee Wilton, Trevor Moodie, Amy Hayden, Sandra Turner, Nicholas Hardcastle, Shankar Siva, Keen-Hun Tai, Sankar Arumugam, Mark Sidhom, Per Poulsen, Val Gebski, Alisha Moore, Paul Keall","doi":"10.1002/mp.17529","DOIUrl":null,"url":null,"abstract":"<div>\n \n \n <section>\n \n <h3> Purpose</h3>\n \n <p>The US National Institutes of Health state that <i>Sharing of clinical trial data has great potential to accelerate scientific progress and ultimately improve public health by generating better evidence on the safety and effectiveness of therapies for patients</i> (https://www.ncbi.nlm.nih.gov/books/NBK285999/ accessed 2024-01-24.). Aligned with this initiative, the Trial Management Committee of the Trans-Tasman Radiation Oncology Group (TROG) 15.01 Stereotactic Prostate Adaptive Radiotherapy utilizing Kilovoltage intrafraction monitoring (KIM) (SPARK) clinical trial supported the public sharing of the clinical trial data.</p>\n </section>\n \n <section>\n \n <h3> Acquisition and Validation Methods</h3>\n \n <p>The data originate from the TROG 15.01 SPARK clinical trial. The SPARK trial was a phase II prospective multi-institutional clinical trial (NCT02397317). The aim of the SPARK clinical trial was to measure the geometric and dosimetric cancer targeting accuracy achieved with a real-time image-guided radiotherapy technology named KIM for 48 prostate cancer patients treated in 5 treatment sessions. During treatment, real-time tumor translational and rotational motion were determined from x-ray images using the KIM technology. A dose reconstruction method was used to evaluate the dose delivered to the target and organs-at-risk. Patient-reported outcomes and toxicity data were monitored up to 2 years after the completion of the treatment.</p>\n </section>\n \n <section>\n \n <h3> Data Format and Usage Notes</h3>\n \n <p>The dataset contains planning CT images, treatment plans, structure sets, planned and motion-included dose-volume histograms, intrafraction kilovoltage, and megavoltage projection images, tumor translational and rotational motion determined by KIM, tumor motion ground truth data, the linear accelerator trajectory traces, and patient treatment outcomes. The dataset is publicly hosted by the University of Sydney eScholarship Repository at https://doi.org/10.25910/qg5d-6058.</p>\n </section>\n \n <section>\n \n <h3> Potential Applications</h3>\n \n <p>The 3.6 Tb dataset, with approximately 1 million patient images, could be used for a variety of applications, including the development of real-time image-guided methods, adaptation strategies, tumor, and normal tissue control modeling, and prostate-specific antigen kinetics.</p>\n </section>\n </div>","PeriodicalId":18384,"journal":{"name":"Medical physics","volume":"52 3","pages":"1941-1949"},"PeriodicalIF":3.2000,"publicationDate":"2024-11-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/mp.17529","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Medical physics","FirstCategoryId":"3","ListUrlMain":"https://onlinelibrary.wiley.com/doi/10.1002/mp.17529","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"RADIOLOGY, NUCLEAR MEDICINE & MEDICAL IMAGING","Score":null,"Total":0}

引用次数: 0

Abstract

Purpose

The US National Institutes of Health state that Sharing of clinical trial data has great potential to accelerate scientific progress and ultimately improve public health by generating better evidence on the safety and effectiveness of therapies for patients (https://www.ncbi.nlm.nih.gov/books/NBK285999/ accessed 2024-01-24.). Aligned with this initiative, the Trial Management Committee of the Trans-Tasman Radiation Oncology Group (TROG) 15.01 Stereotactic Prostate Adaptive Radiotherapy utilizing Kilovoltage intrafraction monitoring (KIM) (SPARK) clinical trial supported the public sharing of the clinical trial data.

Acquisition and Validation Methods

The data originate from the TROG 15.01 SPARK clinical trial. The SPARK trial was a phase II prospective multi-institutional clinical trial (NCT02397317). The aim of the SPARK clinical trial was to measure the geometric and dosimetric cancer targeting accuracy achieved with a real-time image-guided radiotherapy technology named KIM for 48 prostate cancer patients treated in 5 treatment sessions. During treatment, real-time tumor translational and rotational motion were determined from x-ray images using the KIM technology. A dose reconstruction method was used to evaluate the dose delivered to the target and organs-at-risk. Patient-reported outcomes and toxicity data were monitored up to 2 years after the completion of the treatment.

Data Format and Usage Notes

The dataset contains planning CT images, treatment plans, structure sets, planned and motion-included dose-volume histograms, intrafraction kilovoltage, and megavoltage projection images, tumor translational and rotational motion determined by KIM, tumor motion ground truth data, the linear accelerator trajectory traces, and patient treatment outcomes. The dataset is publicly hosted by the University of Sydney eScholarship Repository at https://doi.org/10.25910/qg5d-6058.

Potential Applications

The 3.6 Tb dataset, with approximately 1 million patient images, could be used for a variety of applications, including the development of real-time image-guided methods, adaptation strategies, tumor, and normal tissue control modeling, and prostate-specific antigen kinetics.

Abstract Image

查看原文本刊更多论文

TROG 15.01 利用千伏分段内监测的立体定向前列腺适应性放射治疗（SPARK）临床试验数据库。

目的：美国国立卫生研究院指出，共享临床试验数据具有巨大潜力，可加快科学进步，并通过为患者提供更好的治疗安全性和有效性证据，最终改善公众健康（https://www.ncbi.nlm.nih.gov/books/NBK285999/，访问时间：2024-01-24）。根据这一倡议，跨塔斯曼放射肿瘤学组织（TROG）15.01利用千伏分段内监测（KIM）的立体定向前列腺适应性放疗（SPARK）临床试验管理委员会支持公开共享临床试验数据：数据来源于TROG 15.01 SPARK临床试验。SPARK试验是一项II期前瞻性多机构临床试验（NCT02397317）。SPARK 临床试验的目的是测量名为 KIM 的实时图像引导放疗技术对 48 名前列腺癌患者分 5 次治疗所达到的几何和剂量癌症靶向准确性。在治疗过程中，利用 KIM 技术通过 X 射线图像确定肿瘤的实时平移和旋转运动。剂量重建方法用于评估靶点和危险器官的剂量。数据格式和使用说明：该数据集包含计划CT图像、治疗计划、结构集、计划剂量-体积直方图和包含运动的剂量-体积直方图、分段内千伏和兆伏投影图像、由KIM确定的肿瘤平移和旋转运动、肿瘤运动地面实况数据、直线加速器轨迹和患者治疗结果。该数据集由悉尼大学 eScholarship Repository 公开托管，网址为 https://doi.org/10.25910/qg5d-6058.Potential applications：3.6 Tb 数据集包含约 100 万张患者图像，可用于多种应用，包括开发实时图像引导方法、适应策略、肿瘤和正常组织控制建模以及前列腺特异性抗原动力学。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Medical physics 医学-核医学

CiteScore

6.80

自引率

15.80%

发文量

660

审稿时长

1.7 months

期刊介绍： Medical Physics publishes original, high impact physics, imaging science, and engineering research that advances patient diagnosis and therapy through contributions in 1) Basic science developments with high potential for clinical translation 2) Clinical applications of cutting edge engineering and physics innovations 3) Broadly applicable and innovative clinical physics developments Medical Physics is a journal of global scope and reach. By publishing in Medical Physics your research will reach an international, multidisciplinary audience including practicing medical physicists as well as physics- and engineering based translational scientists. We work closely with authors of promising articles to improve their quality.